Cargando…

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial

BACKGROUND: Rezafungin (RZF) is a novel echinocandin exhibiting distinctive pharmacokinetics/pharmacodynamics. STRIVE was a phase 2, double-blind, randomized trial designed to compare the safety and efficacy of RZF once weekly (QWk) to caspofungin (CAS) once daily for treatment of candidemia and/or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thompson, George R, Soriano, Alex, Skoutelis, Athanasios, Vazquez, Jose A, Honore, Patrick M, Horcajada, Juan P, Spapen, Herbert, Bassetti, Matteo, Ostrosky-Zeichner, Luis, Das, Anita F, Viani, Rolando M, Sandison, Taylor, Pappas, Peter G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Online Only Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662762/ https://www.ncbi.nlm.nih.gov/pubmed/32955088 http://dx.doi.org/10.1093/cid/ciaa1380

Ejemplares similares

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Thompson, George R, et al.
Publicado: (2020)

1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study
por: Thompson, George R, et al.
Publicado: (2018)

637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Vazquez, Jose A, et al.
Publicado: (2020)

Erratum to: Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
Publicado: (2021)

1174. Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations
por: Flanagan, Shawn, et al.
Publicado: (2020)

P22 Patient-level meta-analysis of efficacy and safety from STRIVE and ReSTORE: randomized, double-blinded, multicentre Phase 2 and Phase 3 trials of rezafungin in the treatment of candidaemia and/or invasive candidiasis
por: Soriano, A, et al.
Publicado: (2023)

P27 Rezafungin treatment of candidaemia and invasive candidiasis: outcomes stratified by baseline renal function—analysis of the Phase 2 + Phase 3 trials
por: Sandison, Taylor, et al.
Publicado: (2023)

P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or invasive candidiasis
por: Thompson, G R, et al.
Publicado: (2023)

Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia
por: Gebretekle, Gebremedhin Beedemariam, et al.
Publicado: (2022)

369. Using Hybrid Models and Blockchain Technology as a Means to Develop a Novel Propensity Score for Candidemia and Invasive Candidiasis
por: Rao, Arni Sr Srinivasa, et al.
Publicado: (2018)

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
por: Miesel, Lynn, et al.
Publicado: (2019)

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B
por: Dupont, Bertrand F, et al.
Publicado: (2009)

Caspofungin-Induced Cardiotoxicity in Patients Treating for Candidemia
por: Sattarzadeh Badkoubeh, Roya, et al.
Publicado: (2022)

P28 Rezafungin efficacy and safety in immunocompromised patients: sub-analyses of the Phase 3 trial in treatment of candidaemia and invasive candidiasis
por: Sandison, Taylor, et al.
Publicado: (2023)

Clinical prediction rules for invasive candidiasis in the ICU: ready for prime time?
por: Ostrosky-Zeichner, Luis
Publicado: (2011)

A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis
por: Brand, Stephen R, et al.
Publicado: (2020)

New Formulations Loading Caspofungin for Topical Therapy of Vulvovaginal Candidiasis
por: Pérez-González, Noelia, et al.
Publicado: (2021)

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia
por: Miesel, Lynn, et al.
Publicado: (2021)

2389. Effect of Rezafungin on QT Interval in Healthy Subjects
por: Flanagan, Shawn, et al.
Publicado: (2018)

Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
por: Flanagan, Shawn, et al.
Publicado: (2023)

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
por: Huguet, Jade, et al.
Publicado: (2021)

Treatment of invasive candidiasis with caspofungin in the intensive care unit
por: DiNubile, MJ, et al.
Publicado: (2003)

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species
por: Tóth, Zoltán, et al.
Publicado: (2020)

817. Caspofungin versus Anidulafungin in Patients with Candidemia: Retrospective Comparative Study
por: Elajez, Reem, et al.
Publicado: (2023)

Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans
por: Ong, Voon, et al.
Publicado: (2022)

1173. Ocular Candidiasis in Patients with Candidemia Diagnosed by Blood Culture Versus T2Candida® Assay
por: White, Cameron, et al.
Publicado: (2020)

Invasive candidiasis and candidemia in pediatric and neonatal patients: A review of current guidelines
por: Vasileiou, Eleni, et al.
Publicado: (2018)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature
por: Glöckner, A
Publicado: (2011)

1286. Pharmacokinetics, Excretion, and Mass Balance of [(14)C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults
por: Ong, Voon, et al.
Publicado: (2020)

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum
por: Kovács, Renátó, et al.
Publicado: (2021)

Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis
por: Jeck, Julia, et al.
Publicado: (2023)

Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients
por: Ruhnke, M, et al.
Publicado: (2011)

Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis?
por: van Prehn, Joffrey, et al.
Publicado: (2017)

The Medical Research Council (UK)/Uganda Virus Research Institute Uganda Research Unit on AIDS – ‘25 years of research through partnerships’
por: Kaleebu, P, et al.
Publicado: (2015)

Cognitive Function of Children and Adolescents With Congenital Adrenal Hyperplasia: Importance of Early Diagnosis
por: Messina, Valeria, et al.
Publicado: (2020)

Changes in orthodontics during the COVID-19 pandemic that have come to stay
por: García-Camba, Pablo, et al.
Publicado: (2020)

COVID-19: What do we know?
por: Marshall, Steve, et al.
Publicado: (2020)

Bridging worldviews: Toward a common model of leadership across the health professions
por: Garman, Andrew N., et al.
Publicado: (2020)

IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction
por: Joustra, Sjoerd D, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0nauqbfe8hhh8s1jjmvuu4ba5b